Literature DB >> 30468559

Ablation of interferon regulatory factor 4 in T cells induces "memory" of transplant tolerance that is irreversible by immune checkpoint blockade.

Hedong Zhang1,2, Jie Wu1,3, Dawei Zou1, Xiang Xiao1, Hui Yan1, Xian C Li1,4, Wenhao Chen1,4.   

Abstract

Achieving transplant tolerance remains the ultimate goal in the field of organ transplantation. We demonstrated previously that ablation of the transcription factor interferon regulatory factor 4 (IRF4) in T cells induced heart transplant acceptance by driving allogeneic CD4+ T cell dysfunction. Herein, we showed that heart-transplanted mice with T cell-specific IRF4 deletion were tolerant to donor-specific antigens and accepted the subsequently transplanted donor-type but not third-party skin allografts. Moreover, despite the rejection of the primary heart grafts in T cell-specific Irf4 knockout mice under immune checkpoint blockade, the establishment of donor-specific tolerance in these mice was unhindered. By tracking alloantigen-specific CD4+ T cells in vivo, we revealed that checkpoint blockade restored the expression levels of the majority of wild-type T cell-expressed genes in Irf4-deficient T cells on day 6 post-heart grafting, indicating the initial reinvigoration of Irf4-deficient T cells. Nevertheless, checkpoint blockade did not restore cell frequency, effector memory cell generation, and IFN-γ/TNF-α production of Irf4-/- alloreactive T cells at day 30 post-heart grafting. Hence, targeting IRF4 represents a potential therapeutic strategy for driving intrinsic T cell dysfunction and achieving alloantigen-specific transplant tolerance.
© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  T cell biology; animal models: murine; basic (laboratory) research/science; cellular biology; graft survival; immunobiology; organ transplantation in general; tolerance

Year:  2018        PMID: 30468559      PMCID: PMC6440205          DOI: 10.1111/ajt.15196

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  30 in total

1.  Erosion of Transplantation Tolerance After Infection.

Authors:  J S Young; M D Daniels; M L Miller; T Wang; R Zhong; D Yin; M-L Alegre; A S Chong
Journal:  Am J Transplant       Date:  2016-07-13       Impact factor: 8.086

Review 2.  Transplantation tolerance after allograft rejection.

Authors:  Michelle L Miller; Maria-Luisa Alegre; Anita S Chong
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

3.  Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4+ T Cell Dysfunction.

Authors:  Jie Wu; Hedong Zhang; Xiaomin Shi; Xiang Xiao; Yihui Fan; Laurie J Minze; Jin Wang; Rafik M Ghobrial; Jiahong Xia; Roger Sciammas; Xian C Li; Wenhao Chen
Journal:  Immunity       Date:  2017-12-05       Impact factor: 31.745

4.  CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.

Authors:  Yiyi Yan; Siyu Cao; Xin Liu; Susan M Harrington; Wendy E Bindeman; Alex A Adjei; Jin Sung Jang; Jin Jen; Ying Li; Pritha Chanana; Aaron S Mansfield; Sean S Park; Svetomir N Markovic; Roxana S Dronca; Haidong Dong
Journal:  JCI Insight       Date:  2018-04-19

5.  Tumor Regression and Allograft Rejection after Administration of Anti-PD-1.

Authors:  Evan J Lipson; Serena M Bagnasco; Jack Moore; Sekwon Jang; Manisha J Patel; Andrea A Zachary; Drew M Pardoll; Janis M Taube; Charles G Drake
Journal:  N Engl J Med       Date:  2016-03-03       Impact factor: 91.245

6.  Repeated Injections of IL-2 Break Renal Allograft Tolerance Induced via Mixed Hematopoietic Chimerism in Monkeys.

Authors:  Y Yamada; O Nadazdin; S Boskovic; S Lee; E Zorn; R N Smith; R B Colvin; J C Madsen; A B Cosimi; T Kawai; G Benichou
Journal:  Am J Transplant       Date:  2015-07-17       Impact factor: 8.086

7.  Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade.

Authors:  Nicola J Monk; Roseanna E G Hargreaves; James E Marsh; Conrad A Farrar; Steven H Sacks; Maggie Millrain; Elizabeth Simpson; Julian Dyson; Stipo Jurcevic
Journal:  Nat Med       Date:  2003-09-14       Impact factor: 53.440

8.  Murine skin transplantation.

Authors:  Kym R Garrod; Michael D Cahalan
Journal:  J Vis Exp       Date:  2008-01-16       Impact factor: 1.355

9.  CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade.

Authors:  P A Taylor; R J Noelle; B R Blazar
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

10.  Chromatin states define tumour-specific T cell dysfunction and reprogramming.

Authors:  Mary Philip; Lauren Fairchild; Liping Sun; Ellen L Horste; Steven Camara; Mojdeh Shakiba; Andrew C Scott; Agnes Viale; Peter Lauer; Taha Merghoub; Matthew D Hellmann; Jedd D Wolchok; Christina S Leslie; Andrea Schietinger
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962

View more
  11 in total

1.  CD4+ T cell exhaustion leads to adoptive transfer therapy failure which can be prevented by immune checkpoint blockade.

Authors:  Jinfei Fu; Anze Yu; Xiang Xiao; Juyu Tang; Xiongbing Zu; Wenhao Chen; Bin He
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Resilience of T cell-intrinsic dysfunction in transplantation tolerance.

Authors:  Michelle L Miller; Christine M McIntosh; Ying Wang; Luqiu Chen; Peter Wang; Yuk Man Lei; Melvin D Daniels; Elyse Watkins; Carolina Mora Solano; Anita S Chong; Maria-Luisa Alegre
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-04       Impact factor: 11.205

3.  Genetically targeting the BATF family transcription factors BATF and BATF3 in the mouse abrogates effector T cell activities and enables long-term heart allograft survival.

Authors:  Yixuan Wang; Xiang Xiao; Gangcheng Kong; Mou Wen; Guangchuan Wang; Rafik M Ghobrial; Nianguo Dong; Wenhao Chen; Xian C Li
Journal:  Am J Transplant       Date:  2021-10-15       Impact factor: 8.086

Review 4.  Programmed T cell differentiation: Implications for transplantation.

Authors:  Rebecca L Crepeau; Mandy L Ford
Journal:  Cell Immunol       Date:  2020-03-29       Impact factor: 4.868

5.  T cell exhaustion is associated with antigen abundance and promotes transplant acceptance.

Authors:  Dawei Zou; Yulin Dai; Xiaolong Zhang; Guohua Wang; Xiang Xiao; Peilin Jia; Xian C Li; Zhiyong Guo; Wenhao Chen
Journal:  Am J Transplant       Date:  2020-04-17       Impact factor: 8.086

6.  T follicular helper and memory cell responses and the mTOR pathway in murine heart transplantation.

Authors:  Aini Xie; Hui Yan; Jinfei Fu; Adam He; Xiang Xiao; Xian C Li; Wenhao Chen
Journal:  J Heart Lung Transplant       Date:  2019-11-26       Impact factor: 10.247

7.  Interferon regulatory factor 4 deficiency in CD8+ T cells abrogates terminal effector differentiation and promotes transplant acceptance.

Authors:  Dawei Zou; Jinfei Fu; Zhiyong Guo; Wenhao Chen
Journal:  Immunology       Date:  2020-10-12       Impact factor: 7.397

8.  Autophagy-lysosome inhibitor chloroquine prevents CTLA-4 degradation of T cells and attenuates acute rejection in murine skin and heart transplantation.

Authors:  Jikai Cui; Jizhang Yu; Heng Xu; Yanqiang Zou; Hao Zhang; Shanshan Chen; Sheng Le; Jing Zhao; Lang Jiang; Jiahong Xia; Jie Wu
Journal:  Theranostics       Date:  2020-07-01       Impact factor: 11.556

9.  Transgenic Expression of a Mutant Ribonuclease Regnase-1 in T Cells Disturbs T Cell Development and Functions.

Authors:  Gangcheng Kong; Yaling Dou; Xiang Xiao; Yixuan Wang; Yingzi Ming; Xian C Li
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

10.  IRF4 ablation in B cells abrogates allogeneic B cell responses and prevents chronic transplant rejection.

Authors:  Guohua Wang; Dawei Zou; Yixuan Wang; Nancy M Gonzalez; Stephanie G Yi; Xian C Li; Wenhao Chen; A Osama Gaber
Journal:  J Heart Lung Transplant       Date:  2021-06-23       Impact factor: 13.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.